Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results